Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma

Strahlentherapie und Onkologie

Volumn 179, Issue 9, 2003, Pages 615-619

  Odrazka, Karel ^a   Petera, Jiri ^a   Kohlova, Tereza ^a   Dolezel, Martin ^a   Vaculikova, Miloslava ^a   Zouhar, Milan ^a   Malek, Vaclav ^a   Hobza, Vladimir ^a   Latr, Ivan ^a   Nemecek, Stanislav ^a   Sercl, Miroslav ^b   Ryska, Pavel ^b   Blaha, Milan ^a   Cermakova, Eva ^b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Glioblastoma; Hemoglobin; Radiotherapy

Indexed keywords

DEXAMETHASONE; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN RADIATION; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLIOBLASTOMA; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; PROGNOSIS; RADIATION DOSE; RADIOSENSITIVITY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRAIN NEOPLASMS; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; DEXAMETHASONE; DOSE FRACTIONATION; FEMALE; GLIOBLASTOMA; HEMOGLOBINS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0042825227     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-1097-x     Document Type: Article

References (32)

1. Aydin H, Sillenberg I, Lieven H von. Patterns of failure following CT-based 3-D irradiation for malignant glioma. Strahlenther Onkol 2001;177:424-31.
2. Black PM. Brain tumors. Part 1. N Engl J Med 1991;324:1471-6.
3. Brada M. Current approaches to radiation therapy for malignant gliomas. Front Radiat Ther Oncol 1999;33:139-49.
4. Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
5. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20:1635-42.
6. Collingridge DR, Piepmeier JM, Rockwell S, et al. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoral brain tissue. Radiother Oncol 1999;53:127-31.
7. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972;34: 187-202.
8. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10.
9. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-97.
10. Gamburg ES, Regine WF, Patchell RA, et al. The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2000;48:1359-62.
11. Hohwieler Schloss M, Freidberg SR, Heatley GJ, et al. Glucocorticoid dependency as a prognostic factor in radiotherapy for cerebral gliomas. Acta Oncol 1989;28:51-5.
12. Hulshof MC, Koot RW, Schimmel EC, et al. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution. Strahlenther Onkol 2001;177:283-90.
13. Huncharek M. Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticancer Res 1998;18:1935-9.
14. Kagei K, Shirato H, Nishioka T, et al. High-dose-rate intracavitary irradiation using linear source arrangement for stage II and III squamous cell carcinoma of the uterine cervix. Radiother Oncol 1998;47:207-13.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999;53:99-104.
17. Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-75.
18. Logsdon MD, Eifel PJ. FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys 1999;43:763-75.
19. Lutterbach J, Weigel P, Guttenberger R, et al. Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme. Radiother Oncol 1999;53:49-52.
20. Medical Research Council Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: development of a prognostic index. J Neurooncol 1990;9:47-55.
21. Molls M, Stadler P, Becker A, et al. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998;174:Suppl 4:13-6.
22. Nelson DF, Diener-West M, Weinstein AS, et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys 1986;12:1793-800.
23. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21.
24. Prados MD, Scott CB, Rotman M, et al. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1998;40:653-9.
25. 2 histography in patients with advanced head and neck cancer. Strahlenther Onkol 2001;177:462-8.
26. Shrieve DC, Alexander E 3rd, Black PM, et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 1999;90:72-7.
27. Steltzer KJ, Sauve KI, Spence AM, et al. Corpus callosum involvement as a prognostic factor for patients with high-grade astrocytoma. Int J Radiat Oncol Biol Phys 1997;38:27-30.
28. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-7.
29. Van Acht MJ, Hermans J, Boks DE, et al. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992;23:229-35.
30. Van der Maazen RWM, Thijssen HOM, Kaanders JHAM, et al. Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother Oncol 1995;35:118-22.
31. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333-43.
32. Wilhelm R, Kovacs G, Heindchsohn D, et al. Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin level. Strahlenther Onkol 1998;174:128-32.